Uniqure NV (QURE) was Resumed by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $21. H.C. Wainwright advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on Uniqure NV. Shares were Reiterated by WallachBeth on Jun 15, 2016 to “Buy” and Lowered the Price Target to $ 35 from a previous price target of $60 .
Uniqure NV opened for trading at $7.36 and hit $8.2 on the upside on Tusday, eventually ending the session at $8, with a gain of 8.55% or 0.63 points. The heightened volatility saw the trading volume jump to 8,66,078 shares. Company has a market cap of $198 M.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Companys first product is Glybera for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline it has gene treatments for hemophilia porphyria Parkinson Sanfilippo B syndrome and hearing loss. Additionally it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform including a cost effective manufacturing process. In August 2014 Uniqure NV acquired InoCard GmbH an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.